Search Results - "DMOSZYNSKA, A."

The frequency of T regulatory cells modulates the survival of multiple myeloma patients: detailed characterisation of immune status in multiple myeloma by Giannopoulos, K, Kaminska, W, Hus, I, Dmoszynska, A

“…Background: Multiple myeloma (MM) is an immunoproliferative disease characterised by the uncontrolled proliferation of plasma cells, which is accompanied by…”
Get full text

The candidate immunotherapeutical target, the receptor for hyaluronic acid-mediated motility, is associated with proliferation and shows prognostic value in B-cell chronic lymphocytic leukemia by Giannopoulos, K, Mertens, D, Bühler, A, Barth, T F E, Idler, I, Möller, P, Kröber, A, Greiner, J, Chocholska, S, Dmoszyñska, A, Roliñski, J, Döhner, H, Stilgenbauer, S, Schmitt, M

“…Differential expression of molecules in chronic lymphocytic leukemia (CLL) may define prognostic markers and suitable targets for immunotherapy. Expression of…”
Get full text

Peptide vaccination elicits leukemia-associated antigen-specific cytotoxic CD8 T-cell responses in patients with chronic lymphocytic leukemia by Giannopoulos, K, Dmoszynska, A, Kowal, M, Rolinski, J, Gostick, E, Price, D A, Greiner, J, Rojewski, M, Stilgenbauer, S, Döhner, H, Schmitt, M

“…The receptor for hyaluronic acid-mediated motility (RHAMM) is a tumor-associated antigen in chronic lymphocytic leukemia (CLL). CD8 + T cells primed with the…”
Get full text

Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial by Robak, Tadeusz, Bloński, Jerzy Z., Kasznicki, Marek, Blasińska-Morawiec, Maria, Krykowski, Euzebiusz, Dmoszyńska, Anna, Mrugala-Śpiewak, Halina, Skotnicki, Aleksander B., Nowak, Wieslaw, Konopka, Lech, Ceglarek, Bernadeta, Maj, Stanislaw, Dwilewicz-Trojaczek, Jadwiga, Hellmann, Andrzej, Urasiński, Ignacy, Zdziarska, Barbara, Kotlarek-Haus, Sabina, Potoczek, Stanislaw, Grieb, Pawel

“…The efficacy and toxicity of cladribine (2-CdA) + prednisone (P) versus chlorambucil (Chl) + P were compared in previously untreated patients with progressive…”
Get full text

Thalidomide exerts distinct molecular antileukemic effects and combined thalidomide fludarabine therapy is clinically effective in high-risk chronic lymphocytic leukemia by Giannopoulos, K, Dmoszynska, A, Kowal, M, Wąsik-Szczepanek, E, Bojarska-Junak, A, Rolinski, J, Döhner, H, Stilgenbauer, S, Bullinger, L

“…Thalidomide represents a promising immunomodulatory drug that targets both leukemia cells and the tumor microenvironment. We treated patients with chronic…”
Get full text

TNF-alpha and TNF-beta gene polymorphisms in Polish patients with sarcoidosis. Connection with the susceptibility and prognosis by Kieszko, R, Krawczyk, P, Chocholska, S, Dmoszyńska, A, Milanowski, J

“…Sarcoidosis is a systemic granulomatous disease of unknown aetiology, in which genetic factors, especially the genes of the highly polymorphic MHC region, seem…”
Get full text

The influence of palifermin (Kepivance) on oral mucositis and acute graft versus host disease in patients with hematological diseases undergoing hematopoietic stem cell transplant by NASILOWSKA-ADAMSKA, B, RZEPECKI, P, DUDA, D, SZYDLO, R, HALABURDA, K, SZCZEPINSKI, A, LANGE, A, HELLMAN, A, ROBAK, T, SKOTNICKI, A, JEDRZEJCZAK, W. W, WALEWSKI, J, MANKO, J, HOLOWIECKI, J, KOMARNICKI, M, DMOSZYNSKA, A, WARZOCHA, K, MARIANSKA, B, CZYZ, A, MARKIEWICZ, M, FEDEROWICZ, I, TOMASZEWSKA, A, PIATKOWSKA-JAKUBAS, B, WRZESIEN-KUS, A, BIENIASZEWSKA, M

“…In this multicenter study, we assessed the use of palifermin (recombinant human-keratinocyte growth factor 1) in the prevention of oral mucositis (OM) and…”
Get full text

Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study by HOLOWIECKI, J, GROSICKI, S, ZDZIARSKA, B, DMOSZYNSKA, A, MARIANSKA, B, PLUTA, A, ZAWILSKA, K, KOMARNICKI, M, KLOCZKO, J, SULEK, K, HAUS, O, STELLA-HOLOWIECKA, B, ROBAK, T, BARAN, W, JAKUBAS, B, PALUSZEWSKA, M, WIERZBOWSKA, A, KIELBINSKI, M, JAGODA, K, KYRCZ-KRZEMIEN, S, GIEBEL, S, HELLMANN, A, SKOTNICKI, A, JEDRZEJCZAK, W. W, KONOPKA, L, KULICZKOWSKI, K

“…To assess the efficacy of an original DAC-7 regimen: daunorubicine (DNR) 60 mg/m2/day, days 1-3; cytarabine (AraC) 200 mg/m2/day, days 1-7; cladribine (2-CdA)…”
Get full text

Expression of RHAMM/CD168 and other tumor-associated antigens in patients with B-cell chronic lymphocytic leukemia by GIANNOPOULOS, K, LI, L, BOJARSKA-JUNAK, A, ROLINSKI, J, DMOSZYNSKA, A, HUS, I, GREINER, J, RENNER, C, DÖHNER, H, SCHMITT, M

“…Antigen targeted immunotherapies might represent a novel treatment for B-cell chronic lymphocytic leukemia (B-CLL). We screened the mRNA expression of…”
Get full text

HIGH EFFICACY AND SAFETY OF VTD AS AN INDUCTION PROTOCOL IN NEWLY DIAGNOSED MM PATIENTS ELIGIBLE FOR HDT/AUTOSCT – A REPORT OF POLISH MULTIPLE MYELOMA STUDY GROUP by Hus, I., Manko, J., Jawniak, D., Jurczyszyn, A., Usnarska‐Zubkiewicz, L., Sawicki, M., Charlinski, G., Razny, M., Rodzaj, M., Waszczuk‐Gajda, A., Drozd‐Sokolowska, J., Galazka, A., Swiderska, A., Poglodek, B., Pluta, A., Druzd‐Sitek, A., Grzasko, N., Kopinska, A., Pasternak, A., Blonska, D., Hus, M., Dmoszynska, A.

Get full text

Outcome and prognostic factors in advanced Hodgkin's disease treated with high-dose chemotherapy and autologous stem cell transplantation: a study of 341 patients by Czyż, J., Dziadziuszko, R., Knopińska-Postuszuy, W., Hellmann, A., Kachel, Ł., Hołowiecki, J., Goździk, J., Hansz, J., Avigdor, A., Nagler, A., Osowiecki, M., Walewski, J., Mensah, P., Jurczak, W., Skotnicki, A., Sędzimirska, M., Lange, A., Sawicki, W., Sułek, K., Wach, M., Dmoszyńska, A., Kuś, A., Robak, T., Warzocha, K.

“…Background: The reported probability of survival of patients with Hodgkin's disease (HD) following high-dose chemotherapy with autologous stem cell…”
Get full text

Clinical assessment of Optivate®, a high-purity concentrate of factor VIII with von Willebrand factor, in the management of patients with haemophilia A by DMOSZYNSKA, A., KULICZKOWSKI, K., HELLMANN, A., TRELINSKI, J., KLOCZKO, J., BAGLIN, T., HAY, C., O'SHAUGHNESSY, D., ZAWILSKA, K., MAKRIS, M., SHAIKH-ZAIDI, R., GASCOIGNE, E., DASH, C.

“…Factor VIII (FVIII) concentrates have revolutionized the treatment of patients with haemophilia A. Concerns over the transmission of viral infections through…”
Get full text

Thalidomide treatment of resistant or relapsed multiple myeloma patients by Hus, M, Dmoszynska, A, Soroka-Wojtaszko, M, Jawniak, D, Legiec, W, Ciepnuch, H, Hellmann, A, Wolska-Smolen, T, Skotnicki, A, Manko, J, Polish Multiple Myeloma Study Group

“…Department of Hematology University Medical School, Lublin, Poland. BACKGROUND AND OBJECTIVES: Thalidomide is currently used as a very promising drug in…”
Get full text

Cladribine with or without prednisone in the treatment of previously treated and untreated B‐cell chronic lymphocytic leukaemia — updated results of the multicentre study of 378 patients by ROBAK, T, BLONSKI, J. Z, TOMASZEWSKA, A, HELLMANN, A, LEWANDOWSKI, K, KULICZKOWSKI, K, POTOCZEK, S, ZDZIARSKA, B, HANSZ, J, KROLL, R, KOMARNICKI, M, HOŁOWIECKI, J, KASZNICKI, M, GRIEB, P, KONOPKA, L, CEGLAREK, B, DMOSZYNSK, A, SOROKA-WOJTASZKO, M, SKOTNICKI, A. B, NOWAK, W, DWILEWICZ-TROJACZEK, J

“…Between January 1992 and January 1999, we treated 378 B‐chronic lymphocytic leukaemia (CLL) patients with cladribine (2‐CdA), and 255 of the patients were also…”
Get full text

Experience with Optivate®, a new high purity concentrate of factor VIII with von Willebrand factor, in patients undergoing surgery by HAY, C. R. M., HELLMANN, A., DMOSZYNSKA, A., BAGLIN, T., O'SHAUNESSEY, D., MAKRIS, M., SHAIKH-ZAIDI, R., DASH, C. H.

“…The efficacy and safety of Optivate® was assessed in 23 surgical operations, orthopaedic (12) including 5 revision arthroplasties, ophthalmic (1), ENT (1),…”
Get full text

Pharmacokinetics of Optivate®, a high-purity concentrate of factor VIII with von Willebrand factor, in patients with severe haemophilia A by DMOSZYNSKA, A., HELLMANN, A., BAGLIN, T., O'SHAUGNESSY, D., TRELINSKI, J., KULICZKOWSKI, K., KLOCZKO, J., HAY, C., ZAWILSKA, K., MAKRIS, M., SHAIKH-ZAIDI, R., GASCOIGNE, E., DASH, C.

“…Optivate® is a high purity factor VIII/von Willebrand factor (FVIII/VWF) concentrate, which is manufactured using two antiviral processes: solvent/detergent…”
Get full text

A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Polish Adult Leukemia Group by Wrzesień-Kuś, A, Robak, T, Wierzbowska, A, Lech-Marańda, E, Pluta, A, Wawrzyniak, E, Krawczyńska, A, Kuliczkowski, K, Mazur, G, Kiebiński, M, Dmoszyńska, A, Wach, M, Hellmann, A, Baran, W, Hołowiecki, J, Kyrcz-Krzemień, S, Grosicki, S

“…Purine nucleoside analogues, cladribine (2-chlorodeoxyadenosine, 2-CdA) and fludarabine (FAMP) are active agents in acute myeloid leukemias (AMLs). Synergistic…”
Get full text

An evaluation of factors predicting long-term response to thalidomide in 234 patients with relapsed or resistant multiple myeloma by HUS, I, DMOSZYNSKA, A, SULEK, K, ROBAK, T, KONOPKA, L, KLOCZKO, J, MANKO, J, HUS, M, JAWNIAK, D, SOROKA-WOJTASZKO, M, HELLMANN, A, CIEPLUCH, H, SKOTNICKI, A, WOLSKA-SMOLEN, T

“…The aim of this study was to assess the prognostic value of pretreatment clinical and laboratory parameters in refractory or relapsed multiple myeloma (MM)…”
Get full text

Vaccination of B-CLL patients with autologous dendritic cells can change the frequency of leukemia antigen-specific CD8+ T cells as well as CD4+CD25+FoxP3+ regulatory T cells toward an antileukemia response by Hus, I, Schmitt, M, Tabarkiewicz, J, Radej, S, Wojas, K, Bojarska-Junak, A, Schmitt, A, Giannopoulos, K, Dmoszyńska, A, Roliński, J

“…Recently, we described that vaccination with allogeneic dendritic cells (DCs) pulsed with tumor cell lysate generated specific CD8+ T cell response in patients…”
Get full text

Outcome of treatment in adults with Philadelphia chromosome-positive and/or BCR-ABL--positive acute lymphoblastic leukemia-retrospective analysis of Polish Adult Leukemia Group (PALG) by Wrzesień-Kuś, A, Robak, T, Pluta, A, Zwolińska, M, Wawrzyniak, E, Wierzbowska, A, Skotnicki, A, Jakubas, B, Hołowiecki, J, Nowak, K, Kuliczkowski, K, Mazur, G, Haus, O, Dmoszyńska, A, Adamczyk-Cioch, M, Jedrzejczak, W W, Paluszewska, M, Konopka, L, Pałynyczko, G

“…Patients with Philadelphia chromosome-positive (Ph+) and/or BCR-ABL+ acute lymphoblastic leukemia (ALL) have extremely poor prognoses. Most of these patients…”
Get full text